AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Zacks News
Walgreens (WBA) Expands Medical Care Offerings in California
by Zacks Equity Research
Walgreens' (WBA) new initiative is intended to reduce care gaps and advance care management by providing access to more affordable and convenient services.
AMN or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
Baxter's (BAX) ST Set Receives FDA Nod, to Boost Patient Outcome
by Zacks Equity Research
Baxter's (BAX) ST Set is expected to improve treatments in an acute care environment.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Bruker (BRKR) to Support Biopharma Industries With New Buyout
by Zacks Equity Research
Bruker's (BRKR) recent buyout strengthens the company as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies.
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Shockwave Medical's (SWAV) New Launch to Lower IVL Treatment Time
by Zacks Equity Research
Shockwave Medical's (SWAV) latest global commercial launch is expected to serve a more diverse patient pool.
DexCom's (DXCM) Upcoming Launch to Boost Diabetes Management
by Zacks Equity Research
DexCom's (DXCM) upcoming launch of Dexcom ONE CGM can help people in the U.K. to manage diabetes.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
Medtronic (MDT) Innovations Aid Global Growth, Volume Woe Stays
by Zacks Equity Research
In the neuroscience portfolio, Medtronic (/MDT) is gaining market share in Cranial and Spinal technologies.
Abbott (ABT) Aveir VR Leadless Pacemaker Receives FDA Nod
by Zacks Equity Research
Abbott's (ABT) Aveir VR is a leadless pacemaker designed to treat patients with slow heart rhythms in the United States.
AMN Healthcare Services (AMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $104.17, moving -1.05% from the previous trading session.
Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain
by Zacks Equity Research
Latest data indicates that Accuray's (ARAY) CyberKnife System is effective in providing long-lasting pain relief to patients suffering from TN.
Zimmer Biomet (ZBH) Hurt by China VBP, COVID-Led Staff Shortage
by Zacks Equity Research
Zimmer Biomet (ZBH) expects to face an adverse pricing impact in the first half of 2022, which is being compared to the non-VBP first half of 2021.
Here's Why You Should Retain AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
NextGen (NXGN) Introduces New Integrated Care EHR Solution
by Zacks Equity Research
NextGen's (NXGN) newest solution lends support to comprehensive primary care and behavioral health with intellectual and developmental disabilities.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on impressive growth across its operating segments.
Here's Why You Should Add Bruker (BRKR) Stock to Your Kitty
by Zacks Equity Research
Bruker's (BRKR) Nano Group microelectronics and semiconductor metrology tools continue to perform well on ongoing strength in bookings and backlog.
AMN Healthcare (AMN) Stock Moves Up 12.9%: What's Driving It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) strong segmental performance and upbeat first-quarter guidance.
Here's Why You Should Retain CVS Health (CVS) Stock For Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) owing to continued progress in its consumer-centric digital solutions.
Philips' (PHG) Innovative Product Suite to Cheer Investors
by Zacks Equity Research
Philips (PHG) launches two major cardiological innovations at ACC 2022, adding strength and depth to its existing healthcare portfolio.
3 Reasons to Retain Accuray (ARAY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.
Edwards Lifesciences (EW) Gets FDA Nod for MITRIS RESILIA Valve
by Zacks Equity Research
Edwards Lifesciences' (EW) MITRIS RESILIA valve has been designed to resemble the appearance and function of the native mitral valve.
Bio-Rad (BIO) Thrives on Global Sales and Testing Uptake
by Zacks Equity Research
Bio-Rad's (BIO) underlying Life Science business' core revenues grow on strong uptake of Droplet Digital PCR as well as the qPCR business.
Cardinal Health (CAH) to Extend Medical Distribution Presence
by Zacks Equity Research
Cardinal Health's (CAH) plans to build a new facility in Columbus, OH, can expand its medical distribution footprint in the region.